Cargando…
A Case of Retinal Tear Associated with Use of Sorafenib
Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhib...
Autores principales: | Gaertner, Kelly M., Caldwell, Stephen H., Rahma, Osama E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109517/ https://www.ncbi.nlm.nih.gov/pubmed/25105094 http://dx.doi.org/10.3389/fonc.2014.00196 |
Ejemplares similares
-
Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults
por: Bodea, Jessica, et al.
Publicado: (2022) -
Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021) -
Modulation of Autophagy by Sorafenib: Effects on Treatment Response
por: Prieto-Domínguez, Nestor, et al.
Publicado: (2016) -
Locally Advanced Cancer of the Esophagus, Current Treatment Strategies, and Future Directions
por: Rahma, Osama E., et al.
Publicado: (2012) -
Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)